Mutations in GNAQ and GNA11 account for up to 83% of all uveal melanoma [205,295], which suggests that inhibition of YAP/TAZ activity, either directly or by blocking pathways downstream of GPCRs, may be an effective treatment for this cancer. Here, GNA11 is linked to uveal melanoma.